Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2a study of TAS0953 in cancer cachexia
jRCT2051250073Phase 2Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vepafestinib in cancer anorexia-cachexia syndrome (CACS) (6 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Body weight change from baseline. Started Aug 2025; status: recruiting.
02
Drugs
vepafestinib
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on jRCT2051250073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250073.